Investigating how obstructive sleep apnea affects heart blood vessels through mineralocorticoid receptors
Official title: Coronary artery dysfunction in OSA: Role of mineralocorticoid receptors
Funded at University of Missouri-Columbia · NIH-11089525 · Data updated 2026-11-12
This study is looking at how obstructive sleep apnea affects heart blood vessels in people with obesity and is testing a possible new treatment that could help improve heart health for those dealing with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $598,360 |
| NIH project number | 5R01HL166617-03 |
| Project ID | NIH-11089525 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with obstructive sleep apnea, particularly those who are obese and at risk for cardiovascular disease.
✕Less likely to help
Patients without obstructive sleep apnea or those who do not have cardiovascular issues may not benefit from this research.
What this research studies
This research focuses on understanding the impact of obstructive sleep apnea (OSA) on coronary artery function, particularly in individuals with obesity. It explores how the activation of mineralocorticoid receptors (MR) may contribute to cardiovascular issues associated with OSA. Using a mouse model, the study will examine the effects of MR antagonists on reversing heart blood vessel dysfunction caused by intermittent hypoxia, simulating the conditions of OSA. The goal is to identify potential new treatments that could improve heart health in patients with OSA.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve cardiovascular health in patients suffering from obstructive sleep apnea.
How similar studies have gone: Previous research has shown that targeting mineralocorticoid receptors can have beneficial effects in cardiovascular conditions, suggesting potential for success in this approach.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Badran, Mohammad — University of Missouri-Columbia
- Study coordinator: Badran, Mohammad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.